This health news summary discusses Lonza's exit from capsules and health ingredients, Medicare coverage mandates for Biogen's ...

Furthermore, the Board of Directors of Heineken Holding N.V. will propose at the AGM in April 2025 to reappoint Alexander de Carvalho as non-executive member of the Board of Directors of Heineken ...

Report with market evolution powered by AI - The global biologics contract development and manufacturing organization (CDMO) ...

USA-based Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer ...

Investing.com -- Lonza’s shares rose over 6% on Thursday following the company’s announcement of plans to divest its Capsules ...

By Isabel Demetz (Reuters) -Swiss contract drugmaker Lonza plans to simplify its structure and exit its capsules and health ...

Elevation Oncology has tapped Lonza’s Synaffix to support the expansion of its pipeline, agreeing to pay up to $368 million ...

With a new CEO at the helm, Swiss CDMO Lonza is looking to revivify its business by doubling down on contract manufacturing ...

Recent developments in the health sector include a dosing pause in Keros Therapeutics' drug trial, Corcept Therapeutics' ALS ...

Lonza forecasts 2025 CER sales growth of nearly 20%, supported by organic growth and acquisitions, with CORE EBITDA margins nearing 30%. The streamlined organizational model, operational by Q2 2025, ...

The life-sciences company will focus on its core business, including drug development, with restructuring and a divestment ...